BioUtah’s Entrepreneur & Investor Summit Puts Utah’s Life Sciences Capital Pipeline on Display Tomorrow

11 March 2026 — Salt Lake City — Utah’s life sciences startup and investment ecosystem will take center stage Thursday as BioUtah convenes founders, investors, researchers, and healthcare innovators for its 2026 Entrepreneur & Investor Life Sciences Summit in downtown Salt Lake City.

Presented by BioUtah in partnership with Brigham Young University’s College of Life Sciences and the BYU Technology Transfer Office, the March 12, 2026 event is framed as Utah’s premier gathering focused specifically on life sciences investment, entrepreneurship, and commercialization.

{NOTE: A second day of networking for investors and companies seeking funding will be held on Friday, March 13 at Snowbird Ski & Summer Resort. That said, the bulk of this writeup will focus on activities happening tomorrow.}

According to a Media Advisory published by BioUtah earlier this week, over 500 attendees are expected the two-day event.

For those in the know, this matters because Utah’s life sciences sector is no longer a niche ecosystem anymore.

In fact, according to BioUtah data, the industry now contributes more than $22.6 billion to state GDP and supports approximately 180,000 jobs statewide. 

For Utah Money Watch readers, the real story is not simply that another conference is arriving on the calendar.

Instead, this Summit offers a concentrated look at how Utah is trying to finance, scale, and commercialize its next generation of life sciences, biotech, medtech, pharmaceuticals, and healthcare companies.

A More Investor-Focused Summit in 2026

For example, if BioUtah’s fall Life Sciences Summit functions as a broad statewide showcase for the sector, this March confab appears designed to push harder on the question of capital.

The agenda is full of sessions about venture funding, startup formation, tech transfer, investor communications, and non-dilutive financing.

From my perspective, the centerpiece of the event is a Shark Tank-style pitch competition where 12 emerging life sciences companies will present to investors and industry leaders across four categories:

🔹 Therapeutics/Pharmaceuticals;

🔹 Medical Device and Diagnostics (Series A funding level prospects);

🔹 Medical Device and Diagnostics (Pre-Series A funding level prospects); and

🔹 Digital Health/Biotech.

Tomorrow's event is less about celebrating the industry in the abstract and more about showing where capital, operators, and innovation may actually meet.

Heavyweight Market and Strategy Voices

The Summit's morning session suggests BioUtah wants the conversation anchored by national-grade market and strategy perspectives, not just local boosterism.

Among the top speakers are Monica DiCenso, head of Global Investment Opportunities Group at J.P. Morgan, who is scheduled to deliver a keynote on market perspectives for 2026, and Ann Somers Hogg of The Clayton Christensen Institute, who will speak on how to build innovations that win.

Another early panel that caught my attention— “Investing in Life Sciences Companies: How the VC Landscape is Changing” — features participants from

• Thiel Capital - Bio Fund, 
• Zandia Ventures, 
• Lumira Ventures, and 
• PL Capital.

Another session I find notable is titled — “Lessons Learned in Building a Life Sciences Company” session — which includes executives from CSL Limited, RefloDX, Biomerics, and Sera Prognostics. 

The Startup Pitch Competition May Be the Most Important Part of the Summit

However, from a Utah Money Watch perspective, the most concrete signal about the potential import of tomorrow's Summit may come in the afternoon pitch competition.

Specifically, the Media Advisory noted 12 startups seeking capital will present technologies spanning biotechnology, medical devices, diagnostics, and digital health.

Listed in alphabetical order, these companies include

• Azunic AI,
• Bloom Surgical, 
• DigiBeat Health, 
• Freyya, 
• Glafabra,
• Intactis Bio,
• Microvascular Therapeutics, 
• Myxtek Bio, 
• Numiera, 
• Path Fertility, 
• Purgo Scientific, and
• UV Sense.   

For investors, these 12 firms provide a high-level curated look at the pipeline in the BioUtah ecosystem.

Conversely, for founders, it creates (at a minimum) visibility.

At the same time, for Utah’s broader innovation economy, this Shark Tank-like opportunity creates a public test of whether the state can continue moving promising science and engineering toward financeable growth.

Universities, Venture Capital, and Company Creation

Another reason this summit deserves attention is the number of ecosystem builders showing up in one place.

The entrepreneur track includes a session on university tech transfer with representatives from BYU, the University of Utah, Utah State University, and Utah Valley University.

Another session will examine how the new BYU School of Medicine can inspire innovation and research. 

Meanwhile, the finance and legal track includes both a seed fund investor panel and a session bluntly titled — “Yes, There is Venture Capital in Utah” — a discussion that will feature participants from Epic Ventures/University of Utah Ventures, MedMountain Ventures, SpringTide, and Wasatch Health. 

Additionally, the lunch keynote address — "An Entrepreneur's Journey" — will be delivered by David Bearss, Ph.D. a veteran of over 25 years in the biotech industry, who currently serves as CEO, President and Co-Founder of Lehi, Utah-based Halia Therapeutics.

{NOTE: By my count, Bearss has served as an executive, board member, and/or advisor for 20 firms in the life sciences field, and that doesn't include positions in academia.}

In other words, not only is BioUtah spotlighting inventors and startup founders.

It's also spotlighting the support architecture required to turn innovation into companies, and companies into durable economic value.

The Practical Value of Roundtable Discussions

One of the more interesting additions to this year’s event is the new roundtable format.

The agenda says the expert-led roundtables are designed to help life sciences companies anticipate challenges, avoid pitfalls, and maximize innovation.

Alphabetized topics include

• AI Use Inside Startups,
• Best Practices for Pitching to Investors,
• Department of Defense Contracting,
• Funding Options Available through Nucleus Institute programs,
• Government Grants,
• Investor Relations, and
• IT Strategy.

This addition of expert-led roundtables to tomorrow's Summit may be one of the strongest indicators of where Utah’s ecosystem is maturing.

From my experience, early-stage founders need a lot more than capital.

Typically, they often need practical help with the unglamorous mechanics of building investor-ready, regulator-ready, and commercially credible companies.

Why Tomorrow's Summit Matters

As described in the Media Advisory and on the BioUtah website, this week's Summit is a gathering point for entrepreneurs, investors, universities, and healthcare leaders to accelerate commercialization and strengthen Utah’s innovation economy.

And from my perspective, that's good, because Utah already has scale in life sciences marketplace.

The next question, however, is depth.

In other words,

🔺 Can the state keep producing fundable startups?
🔺 Can it widen the pool of local and out-of-state investors willing to back them?
🔺 Can universities, operators, and venture firms keep tightening the loop between research, company formation, and commercial execution?

Answering questions like these, especially when applied to the state's life sciences, biotech, medtech, pharmaceuticals, and healthcare industry organizations, entrepreneurs, and ecosystem.

In other word, Thursday’s event is not just a networking exercise.

It's a working snapshot of whether Utah’s life sciences sector is becoming a more complete and self-reinforcing capital / commercialization engine.

And in a state increasingly defined by the race to finance and scale innovation, that is very much a money story.

And that's what I will be looking to decipher/uncover tomorrow.

I hope to see you there.

Closing Note

Yes, even at this late date, less than 24 hours before the start of BioUtah's 2026 Entrepreneur & Investor Life Sciences Summit, it's still possible to snag your slot as an attendee.

Tomorrow's event will be held at the Salt Lake Hilton in downtown Salt Lake City and will run from 7:30am to 5pm.

Tickets start at $250/person, while price to participate in the Ski Day on Friday are $195/person.

Please click here to purchase tickets.

Publisher's Note

This writeup was originally published and distributed to our Subscribers at approximately 7:35am MT on Wednesday, 11 March 2026.

However, if this report/article came to your attention sometime after this date/time and you'd like to change that, then (to become a subscriber), please 

1. Click on a "Subscribe" button on any Utah Money Watch webpage (visit www.UtahMoneyWatch.com),
2. Enter in your name in the proper field in the popup window that appears on-screen, and
3. Enter your preferred email address in the proper field too.

That's it. Thanks.

Team Utah Money Watch